Navigation Links
Simcere Pharmaceutical Group Reports Preliminary Unaudited Fourth Quarter And Full Year 2012 Results
Date:3/7/2013

NANJING, China, March 7, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2012.

Highlights

  • Total revenue was RMB540.1 million (US$86.7 million) for the fourth quarter of 2012, compared to RMB511.0 million for the same period in 2011, representing an increase of 5.7%. For the full year of 2012, total revenue was RMB2,083.0 million (US$334.3 million), representing an increase of 2.1% from RMB2,040.5 million  in 2011.
  • Gross margin for the fourth quarter of 2012 was 81.1%, compared to 82.3% for the same period in 2011. For the full year of 2012, gross margin was 82.7%, compared to 83.9% in 2011.
  • Loss from operations for the fourth quarter of 2012 was RMB78.2 million (US$12.5 million), primarily due to a non-cash impairment charge of RMB97.2 million(US$15.6 million), as the result of a write-down of intangible assets, goodwill, and assets held for sale associated with the acquisition of Jiangsu Quanyi Biological Technology Stock Co., Ltd. ("Jiangsu Quanyi") in 2009. For the full year of 2012, income from operations was RMB39.6 million (US$6.4 million), which represented a decrease of 72.4% from RMB143.5 million in 2011.
  • Net loss attributable to Simcere for the fourth quarter of 2012 was RMB20.8 million (US$3.3 million), compared to net income attributable to Simcere of RMB42.8 million for the same period in 2011. For the full year of 2012, net income attributable to Simcere was RMB57.0 million (US$9.1 million), which represented a decrease of 68.1% from RMB178.4 million in 2011.
  • Mr. Hongquan Liu, Executive Director and Chief Executive Officer of Simcere Pharmaceutical Group, commented, "With the ongoing implementation of a series of healthcare reform policies, drug prices continued to trend down in 2012. Despite the challenging environment and intense competition, our sales in the fourth quarter grew moderately. While we believe market conditions will remain challenging in 2013, our priorities will continue to be strengthening promotion of our key products, accelerating market access and hospital listings, and reducing costs."

    The Company also announced that Mr. Alan Au joined the Company as an independent director and chairman of the audit committee in March 2013. Mr. Au has over 15 years of experience in the financial service and investment sectors relating to healthcare in Asia. He is a Certified Public Accountant in the U.S. and holds the Chartered Financial Analyst designation. Mr. Au received his Bachelor's degree in Psychology from the Chinese University of Hong Kong in 1995, and a Master's degree in Management from Columbia University in 2007.

    2012 Fourth Quarter and Full Year Financial Results Total revenue for the fourth quarter of 2012 was RMB540.1 million (US$86.7 million), compared to RMB511.0 million for the same period in 2011, representing an increase of 5.7%. For the full year of 2012, total revenue was RMB2,083.0 million (US$334.3 million), representing an increase of 2.1% from RMB2,040.5 million  in 2011.

    The tables below set forth the Company's top 10 products by revenue for the three months ended December 31, 2012 and the year ended December 31, 2012:In ThousandsThree months ended December 31, 2012Three months ended December 31, 2011RMBUSD% of totalRMB% of totalChangeProductsTherapeutic ArearevenuerevenueEdaravone

    Neuroscience184,60129,63134.2%172,30333.7%

    7.1%Endu

    Oncology77,56712,45014.4%65,39712.8%

    18.6%Zailin

    Infectious Disease53,6428,6109.9%56,79011.1%

    (5.5%)Yintaiqing

    Inflammation48,6867,8149.0%56,44311.0%

    (13.7%)Sinofuan

    Oncology38,2446,1397.1%42,7898.4%

    (10.6%)Biqi

    Gastroenterology19,6223,1493.6%11,7862.3%

    66.5%Jiebaishu

    Oncology15,7722,5322.9%18,6963.7%

    (15.6%)Kechuanning

    Respiratory 13,1322,1082.4%13,3512.6%

    (1.6%)Anqi

    Infectious Disease11,0731,7772.1%12,9572.5%

    (14.5%)Anxin

    Infectious Disease10,7221,7212.0%10,8772.1%

    (1.4%)Others67,07910,76712.4%49,6319.8%

    35.2%Total540,14086,698100.0%511,020100.0%

    5.7%Year ended December 31, 2012Year ended December 31, 2011RMBUSD% of totalRMB% of totalChangeProductsTherapeutic ArearevenuerevenueEdaravone

    Neuroscience702,698112,79133.7%770,96737.8%

    (8.9%)Endu

    Oncology271,21443,53313.0%263,04612.9%

    3.1%Zailin

    Infectious Disease229,30336,80611.0%191,0069.4%

    20.1%Yintaiqing

    Inflammation177,88428,5528.5%185,4419.1%

    (4.1%)Sinofuan

    Oncology159,88425,6637.7%178,1468.7%

    (10.3%)Biqi

    Gastroenterology86,24213,8434.1%82,0344.0%

    5.1%Jiebaishu

    Oncology69,55311,1643.4%68,3443.3%

    1.8%Anxin

    Infectious Disease56,3969,0522.7%45,9192.3%

    22.8%Anqi

    Infectious Disease51,4958,2652.5%58,5922.9%

    (12.1%)Kechuanning

    Respiratory 46,3577,4412.2%42,2682.0%

    9.7%Others231,94037,22911.2%154,7847.6%

    49.8%Total2,082,966334,339100.0%2,040,547100.0%

    2.1% 

    For more information about the above products, please visit the Company's corporate website:

    www.simcere.com.Gross margin for the fourth quarter of 2012 was 81.1%, compared to 82.3% for the same period in 2011. For the full year of 2012, gross margin was 82.7%, compared to 83.9% in 2011.

    Research and development expenses for the fourth quarter of 2012 totaled RMB60.2 million (US$9.7 million) which represented a decrease of 14.7% from RMB70.6 million for the same period in 2011. This was due primarily to an addition of RMB7.9 million (US$1.3 million) in government research and development grants recognized compared to the same period in 2011. As a percentage of total revenue, research and development expenses decreased to 11.1% for the fourth quarter of 2012 from 13.8% for the same period in 2011. For the full year of 2012, research and development expenses totaled RMB228.7 million (US$36.7 million), compared to RMB198.7 million in 2011.

    Sales, marketing and distribution expenses for the fourth quarter of 2012 were RMB284.5 million (US$45.7 million), which represented a decrease of 1.0% from RMB287.4 million for the same period in 2011. As a percentage of total revenue, sales, marketing and distribution expenses decreased to 52.7% for the fourth quarter of 2012 from 56.2% for the same period in 2011. For the full year of 2012, sales, marketing and distribution expenses were RMB1,140.8 million (US$183.1 million), which represented an increase of 0.8% from RMB1,132.0 million in 2011.

    General and administrative expenses were RMB74.4 million (US$11.9 million) for the fourth quarter of 2012, which represented a decrease of 1.8% from RMB75.8 million for the same period in 2011. As a percentage of total revenue, general and administrative expenses decreased to 13.8% for the fourth quarter of 2012 from 14.8% for the same period in 2011. For the full year of 2012, general and administrative expenses were RMB256.0 million (US$41.1 million), which represented a decrease of 11.2% from RMB288.1 million in 2011.

    Share-based compensation expenses, which were allocated to research and development expenses, sales, marketing and distribution expenses, and general and administrative expenses, based on the nature of the work that the relevant employee was assigned to perform, totaled RMB10.0 million (US$1.6 million) for the fourth quarter of 2012, compared to RMB6.3 million for the same period in 2011, which was primarily due to new issuance of restricted shares. For the full year of 2012, share-based compensation expenses totaled RMB20.4 million (US$3.3 million), a decrease of 30.4% from RMB29.3 million in 2011, which was primarily due to the completion of the vesting period of the first and second batches of restricted shares in November 2011 and March 2012, respectively.

    Loss from operations for the fourth quarter of 2012 was RMB78.2 million (US$12.5 million), compared to income from operations of RMB1.6 million for the same period in 2011. Loss from operations was primarily attributable to a non-cash impairment charge of RMB97.2 million (US$15.6 million) as the result of a write-down of intangible assets, goodwill, and assets held for sale associated with the acquisition of Jiangsu Quanyi in 2009. Simcere has determined a write-down of assets and goodwill of Jiangsu Quanyi is required due to lowered expectation for future sales and profitability of its vaccine products currently under development. For the full year of 2012, income from operations was RMB39.6 million (US$6.4 million), which represented a decrease of 72.4% from RMB143.5 million in 2011.

    Income tax benefit for the fourth quarter of 2012 was RMB11.9 million (US$1.9 million), compared to income tax benefit of RMB41.9 million for the same period in 2011. The significant income tax benefit in the fourth quarter of 2011 was primarily due to the improved financial results at one of the Company's subsidiaries during 2011, resulting in the reversal of the valuation allowance previously made against the deferred tax assets of this subsidiary amounting to RMB32.3 million in the fourth quarter of 2011. For the full year of 2012, income tax benefit was RMB5.6 million (US$0.9 million), compared to income tax benefit of RMB35.4 million in 2011.

    Net loss attributable to Simcere for the fourth quarter of 2012 was RMB20.8 million (US$3.3 million), compared to net income attributable to Simcere of RMB42.8 million for the same period in 2011. The net loss, as mentioned previously, was primarily attributable to the non-cash impairment charge of RMB97.2 million (US$15.6 million) as the result of a write-down of intangible assets, goodwill and assets held for sale associated with the acquisition of Jiangsu Quanyi in 2009. For the full year of 2012, net income attributable to Simcere was RMB57.0 million (US$9.1 million), which represented a decrease of 68.1% from RMB178.4 million in 2011. Net margin, representing net income attributable to Simcere divided by total revenue, for the full year of 2012 was 2.7%, compared to 8.7% in 2011.

    Basic and diluted net loss per American Depository Share ("ADS") for the fourth quarter of 2012 were RMB 0.40 (US$0.06) and RMB 0.39 (US$0.06), respectively. Basic and diluted earnings per ADS for the full year of 2012 were RMB1.06 (US$0.17) and RMB1.06 (US$0.17), respectively. One ADS represents two ordinary shares of the Company.

    As of December 31, 2012, the Company had cash, cash equivalents and restricted cash of RMB201.6 million (US$32.4 million), compared to RMB262.6 million as of December 31, 2011.

    Financial InformationThe preliminary unaudited condensed consolidated statements of income and balance sheets accompanying this press release have been prepared by management using U.S. GAAP. This preliminary financial information is not intended to fully comply with U.S. GAAP because it does not present all of the financial information and disclosures required by U.S. GAAP.

    Safe Harbor StatementThis press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions. In particular, the quotations from management in this press release contain forward-looking statements. These forward looking statements are based upon management's current views and expectations with respect to future events and are not a guarantee of future performance. Furthermore, these statements are, by their nature, subject to a number of risks and uncertainties that could cause actual performance and results to differ materially from those discussed in the forward-looking statements as a result of a number of factors. Further information regarding these and other risks is included in Simcere's filings with the U.S. Securities and Exchange Commission at www.sec.gov. Simcere does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

    Conference CallSimcere Pharmaceutical Group will host a conference call to discuss the Company's results for the fourth quarter and full year of 2012 on Thursday, March 7, 2013 at 8:00 a.m. Eastern Time (Thursday, March 7 at 9:00 p.m. Beijing/Hong Kong time). The management team will be on the call to discuss the results for the fourth quarter and full year of 2012 and to answer questions.

    To access the conference call, please dial:International toll:+65.6723.9381United States toll-free:+1.866.519.4004United States toll:+1.718.354.1231China Domestic toll-free:800.819.0121 China Domestic mobile toll-free:400.620.8038 Hong Kong toll:+852.2475.0994Please ask to be connected to Q4 2012 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 12783585.

    Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.

    Following the earnings conference call, an archive of the call will be available by dialing:United States toll-free:+1.855.452.5696United States toll:+1.646.254.3697 The passcode for replay participants is 12783585. The telephone replay also will be archived on the "Investor Relations" section of the company's website for seven days following the earnings announcement.

    About Simcere Pharmaceutical GroupSimcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.

    Investor and Media Contacts:
    Email: ir@simcere.com In Nanjing:In the United States:Jie Liu D'EliaCindy ZhengVice President

    Brunswick GroupSimcere Pharmaceutical GroupTel: 1-212-333-3810Tel: 86-25-8556-6666*8857In Beijing: Yue YuBrunswick GroupTel: 86-10-5960-8600 

     Simcere Pharmaceutical GroupPRELIMINARY UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME
    (Amounts expressed IN THOUSANDS, EXCEPT SHARE AND ADS DATA)   Three months ended December 31,Year ended December 31,201120122012201120122012RMBRMBUSDRMBRMBUSDProduct revenue

    511,020

    540,140

    86,6982,040,547

    2,082,966

    334,339Total revenue511,020540,14086,6982,040,5472,082,966334,339Cost of materials and production

    (90,614)

    (101,935)

    (16,361)(328,159)

    (361,071)

    (57,956)Gross profit420,406438,20570,3371,712,3881,721,895276,383Operating expenses and other operating income:Research and development

    (70,583)

    (60,216)

    (9,666)(198,722)

    (228,717)

    (36,711)Sales, marketing and distribution

    (287,428)

    (284,518)

    (45,668)(1,131,974)

    (1,140,810)

    (183,113)General and administrative

    (75,784)

    (74,384)

    (11,940)(288,144)

    (255,999)

    (41,091)Impairment on goodwill, intangible assets

    and assets held for sale

    -

    (97,247)

    (15,609)-

    (97,247)

    (15,609)Other operating income

    15,000

    -

    -50,000

    40,439

    6,491Income/(loss)  from operations

    1,611

    (78,160)

    (12,546)143,548

    39,561

    6,350Interest income

    1,036

    1,256

    2024,676

    4,066

    653Interest expense

    (11,034)

    (13,897)

    (2,231)(42,342)

    (69,258)

    (11,117)Foreign currency exchange gains/(losses)

    1,108

    (81)

    (13)7,732

    (923)

    (148)Other  income

    846

    3,244

    52115,036

    11,429

    1,834Equity in (losses)/incomes of equity method
    affiliated company

    (1,974)

    6,062

    973(12,192)

    (4,859)

    (780)Income/(loss)  before income taxes  (8,407)(81,576)(13,094)116,458(19,984)(3,208)Income tax benefit

    41,866

    11,919

    1,91335,371

    5,581

    896Net Income/(loss)33,459(69,657)(11,181)151,829(14,403)(2,312)Less: Net loss attributable to the
    noncontrolling interest9,33848,8577,84226,560

    71,360

    11,454Net income/(loss) attributable to Simcere42,797

    (20,800)

    (3,339)178,389

    56,957

    9,142Income/(loss)  per share attributable to Simcere:Basic

    0.39

    (0.20)

    (0.03)1.63

    0.53

    0.09Diluted

    0.39

    (0.20)

    (0.03)1.61

    0.53

    0.09Income/(loss)  per ADS attributable to Simcere:Basic

    0.78

    (0.40)

    (0.06)3.25

    1.06

    0.17Diluted

    0.77

    (0.39)

    (0.06)3.23

    1.06

    0.17Weighted average number of common shares: Basic

    109,941,646

    105,220,991

    105,220,991109,738,705

    106,996,531

    106,996,531Diluted

    110,477,166

    105,764,663

    105,764,663110,525,257

    107,370,830

    107,370,830 

     

    SIMCERE PHARMACEUTICAL GROUPPRELIMINARY UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS(AMOUNTS EXPRESSED IN THOUSANDS) December 31,December 31,December 31,2011RMB2012RMB2012USDAssetsCurrent assetsCash, cash equivalents and restricted cash

    262,557

    201,556

    32,352Assets held for sale

    -

    90,550

    14,534Bills receivable

    814,822

    679,630

    109,088Accounts receivable, net

    462,050

    413,481

    66,368Inventories

    126,708

    120,932

    19,411Other current assets

    181,196

    237,248

    38,081Total current assets1,847,3331,743,397279,834Property, plant and equipment, net

    925,815

    853,546

    137,004Land use rights

    139,707

    128,220

    20,581Goodwill and intangible assets, net

    648,408

    519,334

    83,359Investments in and advance to an affiliated company

    91,355

    56,785

    9,115Other non-current assets

    81,499

    71,381

    11,457Total assets3,734,117

    3,372,663

    541,350LiabilitiesCurrent liabilitiesShort-term borrowings and current portion of long-term
    borrowings

    816,150

    675,779

    108,470Accounts payable

    52,191

    47,136

    7,566Bills payable

    28,379

    15,000

    2,408Other payables and accrued liabilities

    565,827

    471,603

    75,697Total current liabilities1,462,5471,209,518194,141Long-term borrowings, excluding current portion

    -

    2,000

    321Deferred tax liabilities

    46,248

    56,120

    9,008Other liabilities

    31,625

    32,657

    5,242Total liabilities1,540,4201,300,295208,712Shareholders' equitySimcere shareholders' equity Ordinary shares at par

    8,532

    8,258

    1,326Additional paid-in capital

    954,750

    853,551

    137,004Accumulated other comprehensive loss

    (104,608)

    (104,147)

    (16,717)Retained earnings

    1,197,507

    1,254,464

    201,355Total equity attributable to Simcere2,056,1812,012,126322,968Noncontrolling interest137,51660,2429,670Total shareholders' equity2,193,6972,072,368332,638Commitments and contingenciesTotal liabilities and shareholders' equity3,734,117

    3,372,663

    541,350Note: The conversions of Renminbi (RMB) into United States dollars (USD) as at the reporting dates are based on the noon buying rate of USD1.00 = RMB6.2301 on December 31, 2012 as set forth in the H. 10 statistical release of the Federal Reserve Board. No representation is intended to imply that the RMB amounts could have been, or could be, converted, realized or settled into U.S. dollars at that rate on the reporting dates.


    '/>"/>
    SOURCE Simcere Pharmaceutical Group
    Copyright©2012 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2012 Financial Results on Thursday, March 7, 2013
    2. Simcere Pharmaceutical Group Announces Sale of Equity Interest in Shanghai Celgen
    3. Simcere Pharmaceutical Group Reports Preliminary Unaudited Third Quarter 2012 Results
    4. Simcere Pharmaceutical Group to Announce Third Quarter 2012 Financial Results on Thursday, November 15, 2012
    5. Simcere Pharmaceutical Group Announces Appointment of New Chief Executive Officer
    6. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2012 Results
    7. Simcere Pharmaceutical Group to Announce Second Quarter 2012 Financial Results on Friday, August 10, 2012
    8. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
    9. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
    10. For International Life Sciences, Biotech and Pharmaceutical Events, Top Executives Turn to Global Information
    11. HUYA Bioscience Announces Partnership With Shanghai Zhangjiang Biotech Pharmaceutical Base
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Surgical Procedure Volumes: Global Analysis (United States, ... Australia, Canada)" report to their offering. ... an essential tool for healthcare business planners, provides surgical ... looks at surgery trends with an in-depth analysis of ...
    (Date:6/23/2016)... , June 23, 2016 ... but it continues to present great opportunities to investors. ... for today: Intrexon Corp. (NYSE: XON ), ... Pharmaceuticals Inc. (NASDAQ: ARNA ), and Regeneron ... about these stocks and receive your complimentary trade alerts ...
    (Date:6/23/2016)... Leading BioSciences Inc., a clinical-stage biopharmaceutical ... from a breakdown of the mucosal barrier, today ... as chief executive officer. Mr. Doyle, a ... and board of directors, previously served as chief ... provide continued leadership and strategic direction to the ...
    Breaking Medicine Technology:
    (Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from PsychTests.com ...
    (Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
    (Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are ... for this recognition are considered among the top 2 percent of lawyers practicing within ... of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, ...
    (Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
    (Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... ... Haute Living, is proud to recognize Dr. Barry M. Weintraub as a prominent ... “the most beautiful women in the world, and the most handsome men, look ...
    Breaking Medicine News(10 mins):